Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
Cell Reports · 2026-07 · 45 (7) · 117627
DOI: 10.1016/j.celrep.2026.117627 ↗Kurz gefasst
Korrektur in der Zeitschrift Cell Reports, 2026-07. Verfasst von Andrew M Waters und 36 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
To identify therapeutic targets for KRAS-mutant pancreatic cancer, we conducted a druggable genome siRNA screen and determined that suppression of BCAR1 sensitizes pancreatic cancer cells to ERK inhibition. Integrative analysis of genome-scale CRISPR-Cas9 screens also identified BCAR1 as a top synthetic lethal interactor with mutant KRAS. BCAR1 encodes the SRC substrate p130Cas. We determined that SRC inhibitor-mediated suppression of p130Cas phosphorylation impairs MYC transcription through a DOCK1-RAC1-beta-catenin dependent mechanism. Additionally, genetic suppression of TUBB3, encoding the betaIII-tubulin subunit of microtubules, or pharmacological inhibition of microtubule function, decreased levels of MYC protein and potently sensitized pancreatic cancer cells to ERK inhibition. Accordingly, the combination of a dual SRC/tubulin inhibitor with an ERK inhibitor cooperated to reduce MYC protein and to synergistically suppress the growth of KRAS-mutant pancreatic cancer. Thus, we demonstrate that mechanistically diverse combinations with ERK inhibition suppress MYC to impair pancreatic cancer proliferation.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R., Edwards, A. C., Walsh, K. H., Sulahian, R., McFarland, J. M., Kapner, K. S., Gilbert, T. S. K., Stalnecker, C. A., Javaid, S., Barkovskaya, A., Grover, K. R., Hibshman, P. S., Blake, D. R., …, & Der, C. J. (2026). Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports, 45(7), 117627. https://doi.org/10.1016/j.celrep.2026.117627
Vancouver
Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, et al. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports. 2026;45(7):117627. doi:10.1016/j.celrep.2026.117627
BibTeX
@article{Waters2026,
author = {Waters, Andrew M and Khatib, Tala O and Papke, Bjoern and Goodwin, Craig M and Hobbs, G Aaron and Diehl, J Nathaniel and Yang, Runying and Edwards, A Cole and Walsh, Katherine H and Sulahian, Rita and McFarland, James M and Kapner, Kevin S and Gilbert, Thomas S K and Stalnecker, Clint A and Javaid, Sehrish and Barkovskaya, Anna and Grover, Kajal R and Hibshman, Priya S and Blake, Devon R and Schaefer, Antje and Nowak, Katherine M and Klomp, Jennifer E and Hayes, Tikvah K and Kassner, Michelle and Tang, Nanyun and Tanaseichuk, Olga and Chen, Kaisheng and Zhou, Yingyao and Kalkat, Manpreet and Herring, Laura E and Graves, Lee M and Penn, Linda Z and Yin, Hongwei H and Aguirre, Andrew J and Hahn, William C and Cox, Adrienne D and Der, Channing J},
title = {Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {7},
pages = {117627},
doi = {10.1016/j.celrep.2026.117627}
}
EUVIMED